AParadigm Shift: The New Novel Oral Anticoagulation Agents.
Atrial fibrillation (AF) is the most common arrhythmia and represents one-third of the arrhythmia-related hospital admissions in the developed countries. Embolic strokes associated with AF are more severe and disabling. Thromboembolic stroke prevention is a major goal in treatment of AF and Warfarin has successfully served this purpose for many years. Drug-drug interaction and regular monitoring with Warfarin pose a significant challenge where health care system has limited resources; and lack of a well-structured health system, hinders regular International Normalized Ratio (INR) monitoring. Novel oral anticoagulants (NOACs) have opened up a new exciting chapter in the field of anticoagulation in non-valvular atrial fibrillation (NVAF). This review discussed the landmark trials that led to the development of NOACs and explored the potentials of these new agents with simultaneous comparison of Warfarin.
Published In/Presented At
Saeed, W., Burke, J. F., Mirrani, G., Sirinivasa, M., Nabi, U., Hayat, U., Khan Z., & Sardar, M. R. (2016). AParadigm Shift: The New Novel Oral Anticoagulation Agents. Journal Of The College Of Physicians And Surgeons--Pakistan: JCPSP, 26(7), 611-619. doi:2382
Medical Sciences | Medicine and Health Sciences
Department of Medicine, Cardiology Division, Department of Medicine Faculty